Cancer immunotherapy faces a persistent challenge: immune checkpoint inhibitors frequently fail because tumors deploy interconnected suppressive networks that span multiple cell types. This complexity has left many patients without effective treatment options, particularly those whose cancers resist single-target approaches. A breakthrough engineering solution addresses this fundamental limitation through a novel protein degradation system called Receptor-mediated Endolysosomal recYcling Chimera (RECYC). Unlike conventional checkpoint inhibitors that block individual pathways, RECYC simultaneously degrades multiple checkpoint proteins across both tumor cells and immune-suppressive myeloid cells within the tumor microenvironment. The system operates through repeated cycles of protein targeting and degradation, creating sustained disruption of suppressive networks rather than temporary blockade. Laboratory testing demonstrated that RECYC treatment reprogrammed the entire tumor immune landscape, converting immunologically "cold" tumors into "hot" environments capable of mounting effective anti-cancer responses. The multicycle approach proved superior to single-checkpoint targeting in preclinical models, suggesting that coordinated network disruption may be more effective than pathway-specific interventions. This represents a significant departure from current immunotherapy strategies, which typically focus on individual checkpoint molecules like PD-1 or CTLA-4. The engineering approach could potentially overcome resistance mechanisms that limit current treatments, though translation to human applications will require extensive safety validation. The work highlights how systems-level thinking in cancer biology may yield more effective therapeutic interventions than reductionist approaches targeting isolated molecular pathways.